FDA Publishes New Product-Specific Guidelines for Generic Drug Development
Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
On Feb. 16 2023, FDA published a new set of product-specific guidance documents that provide recommendations for developing generic drugs and creates evidence to support abbreviated new drug application (ANDA) approvals, which helps to streamline generic product and ANDA assessment.
The FDA publishes PSGs to help facilitate generic drug competition, supporting greater access to safe, effective, and potentially lower-cost treatments. Additionally, improving access to high-quality, affordable medicines helps the agency’s mission to advance public health.
The recent group of 30 PSGs includes:
- 21 new and 9 revised PSGs
- 21 PSGs for products with no approved ANDAs, including 13 complex products
- 19 PSGs for complex products (14 new and 5 revised PSGs), and 13 new PSGs for complex products with no approved ANDAs
- PSGs for products used for treatment of Human Immunodeficiency Virus (HIV), achondroplasia, migraines, hypoglycemia, and other conditions.
Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
The FDA also updated their “Upcoming Product-Specific Guidances for Generic Drug Product Development” website to include PSG revision categories and brief descriptions of the revisions that will help applicants in determining if a PSG revision may impact their generic drug development program.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
